What Autoimmune Diseases Cause Hearing Loss?

More than a dozen autoimmune diseases can damage the structures responsible for hearing, and the hearing loss they produce ranges from a subtle, slowly worsening decline to sudden deafness that strikes within hours. Some conditions target the inner ear directly, while others erode hearing as a downstream consequence of widespread inflammation in blood vessels, joints, or connective tissue. The challenge for patients and clinicians alike is that immune-mediated hearing loss often mimics other causes, making it easy to miss or dismiss until the damage is advanced.

Autoimmune Inner Ear Disease as a Standalone Condition

The condition most directly associated with immune-driven hearing loss is autoimmune inner ear disease, or AIED. It accounts for a small fraction of all sensorineural hearing loss cases, but it is one of the few forms that can respond to treatment if caught early enough. AIED produces progressive hearing loss that typically affects both ears, though not symmetrically; one ear usually worsens faster than the other.¹ Vertigo, tinnitus, and a sensation of ear fullness often accompany the hearing loss.²

The timeline is a distinguishing feature. AIED tends to develop over a window of days to weeks, which sets it apart from the very sudden onset of a vascular event and the very gradual progression of age-related hearing loss. The onset has been described as occurring anywhere from roughly three days to three months.¹ That intermediate pace is actually a clinical clue: if hearing declines too quickly for age-related change but too slowly for a stroke or acoustic trauma, the immune system may be the culprit.

Researchers have identified several inner ear proteins that the immune system may mistakenly attack. Cochlin, a structural protein abundant in the inner ear’s framework, is one of the leading candidates. Studies have shown that cochlin and another protein called beta-tectorin can trigger experimental hearing loss in animal models when targeted by immune cells.³ The search for a definitive biomarker is ongoing, but cochlin antibodies remain the most promising lead.⁴

Why the Immune System Turns on the Inner Ear

Several theories attempt to explain why immune defenses begin attacking the delicate structures of the cochlea. One prominent idea is molecular mimicry: the immune system fights off an infection and, in the process, produces antibodies that happen to match proteins in the inner ear. After the infection clears, those antibodies remain and begin to damage the patient’s own tissue. Another mechanism, sometimes called the bystander effect, involves inflammatory molecules like interleukin-1 and tumor necrosis factor leaking from nearby immune reactions and sparking collateral damage inside the cochlea. A third possibility is that physical injury or prior inflammation exposes inner ear proteins that are normally hidden from immune surveillance, breaking the tolerance the immune system had maintained.²

These pathways are not mutually exclusive. In any given patient, a combination of triggers and vulnerabilities likely converges. That overlap is part of what makes AIED so difficult to pin down with a single diagnostic test.

Granulomatosis with Polyangiitis and Other Vasculitides

Among systemic autoimmune diseases, the vasculitides, conditions that inflame blood vessels, are some of the most aggressive offenders when it comes to hearing. Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is the standout example. In one study, more than 90% of patients with GPA reported hearing-related symptoms including hearing loss, tinnitus, and ear fullness, with hearing thresholds across the frequency range significantly elevated compared to controls.⁵

GPA can cause both types of hearing loss. A study of 36 patients found that roughly half had sensorineural hearing loss from inner ear damage, while a third had conductive hearing loss from inflammation in the middle ear structures.⁶ The conductive type responded better to immunosuppressive drugs: most of those cases improved, while sensorineural hearing loss was more stubborn, with the majority of cases either staying the same or getting worse despite treatment. A particularly troubling finding is that hearing loss sometimes surfaces months to years before the vasculitis itself is diagnosed, meaning the ears can be an early warning sign that the rest of the body has not yet declared.⁶ Another survey of 55 GPA patients found ear involvement in over a third, with serous otitis media (fluid buildup behind the eardrum) being the most common sign on examination.⁷

Polyarteritis nodosa, another vasculitis that attacks medium-sized arteries, can also cause sudden deafness. A temporal bone study in a patient with this disease revealed extensive damage to the cochlea: the organ of Corti was destroyed in portions of the inner ear, the membrane that transmits sound was absent, and blood vessel inflammation was evident throughout the temporal bone.⁸ The severity of pathology underscores how vulnerable the cochlea is when its blood supply is compromised by inflamed arteries.

Rheumatoid Arthritis

Rheumatoid arthritis is not the first disease most people associate with hearing trouble, but the ear contains joints, and RA does not spare them. The ossicles, the tiny chain of bones in the middle ear that transmit sound vibrations from the eardrum to the inner ear, include joints that can be targeted by the same inflammatory process that damages knees and knuckles. A systematic review found that RA can affect both the middle ear joints and the inner ear structures simultaneously.⁹

Animal research has put this in stark visual terms. In a study using mice with collagen-induced arthritis, the space between the incus and stapes bones shrank by more than half, and the stapes bone itself was riddled with hundreds of tiny pores that occupied about 12% of its volume, compared to fewer than 10 pores and less than half a percent of volume in healthy mice.¹⁰ The hearing tests in those animals confirmed that sound was not being conducted properly through the middle ear. The same study could not rule out additional sensorineural damage occurring at the same time, which fits the mixed-type hearing loss pattern seen clinically in RA patients.

Lupus and Antiphospholipid Syndrome

Systemic lupus erythematosus (SLE) attacks hearing through a somewhat different mechanism. Rather than joint erosion, lupus-related hearing loss often involves vascular compromise. The cochlea depends on an exquisitely fragile blood supply, and the clotting abnormalities and vasculitis associated with lupus can choke off that supply quickly. In patients with lupus, bilateral involvement is frequent when sudden hearing loss occurs, and the majority of affected patients test positive for antiphospholipid antibodies, which promote clotting.¹¹

Antiphospholipid syndrome itself, whether occurring alongside lupus or on its own, can trigger episodes that mimic a mini-stroke in the cochlea. One documented case involved a patient with both SLE and antiphospholipid syndrome who experienced sudden hearing loss consistent with a transient ischemic event affecting the blood supply to the inner ear. Hearing recovered, but the episode illustrated how quickly blood-clotting disorders can silence a cochlea.¹²

Sjögren’s Syndrome and the Ear’s Mucosal Defenses

Sjögren’s syndrome primarily dries out the eyes and mouth by attacking moisture-producing glands, but its reach extends further. The disease can affect the middle ear by two routes: blockage of the Eustachian tube from inflammatory nodules or crusts in the nasopharynx, and impaired mucosal defenses in the ear canal and middle ear cavity that leave patients vulnerable to chronic ear infections.¹³

Inner ear damage in Sjögren’s has also been documented at the cellular level. Examination of temporal bones from patients with Sjögren’s syndrome and sensorineural hearing loss revealed severe loss of certain cells within the stria vascularis, a structure that maintains the chemical environment the cochlea needs to function. The auditory nerve cells were also shrunken, with their cross-sectional area reduced by about half compared to normal tissue. Patients with Sjögren’s who had normal hearing showed only mild changes, suggesting the severity of inner ear damage tracks with clinical hearing loss.¹⁴

Cogan’s Syndrome and Vogt-Koyanagi-Harada Disease

Some autoimmune conditions tie hearing loss to eye disease in ways that create a distinctive clinical fingerprint. Cogan’s syndrome is a rare disorder defined by the combination of inflammatory eye disease (interstitial keratitis) and inner ear symptoms that resemble Ménière’s disease, including hearing loss, vertigo, and tinnitus.¹⁵ Systemic inflammation of blood vessels can also occur, making it overlap with the vasculitis category. The hearing loss in Cogan’s syndrome can be severe and progressive, and early aggressive treatment is often emphasized because delaying therapy risks permanent cochlear damage.¹⁶

Vogt-Koyanagi-Harada (VKH) disease takes a different path to a similar destination. In VKH, the immune system attacks melanocytes, the pigment-producing cells found in the eyes, skin, hair, inner ear, and the membranes surrounding the brain. Patients typically develop eye inflammation (uveitis), hearing changes, skin depigmentation, and sometimes meningitis symptoms. The hearing involvement stems from the fact that melanocytes in the stria vascularis of the cochlea play a role in maintaining the inner ear’s electrochemical balance. When those cells are destroyed, hearing suffers.¹⁷ A genetic predisposition involving a specific immune system gene has been identified, which helps explain why VKH clusters in certain populations.

Relapsing Polychondritis, Susac Syndrome, and Other Rare Causes

Several rarer autoimmune diseases also damage hearing, each through a distinct mechanism. Relapsing polychondritis attacks cartilage throughout the body, and the inner ear’s proteoglycan-rich structures are not exempt. Ears, nose, trachea, and joint cartilage bear the brunt, but inner ear involvement can precede the more obvious cartilage inflammation.¹⁸ One reported case described a patient whose first symptom was sudden bilateral hearing loss; the characteristic red, swollen ears and eye inflammation only appeared afterward.¹⁹

Susac syndrome is an immune-mediated condition that targets the tiny blood vessels in three specific locations: the brain, the retina, and the cochlea. The classic presentation is a triad of encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss, often accompanied by vertigo.²⁰ The disease specifically damages the endothelium, the lining of blood vessels, in cerebral, retinal, and inner ear microvasculature.²¹ Not all three components appear simultaneously, which can delay diagnosis considerably.

Cryopyrin-associated periodic syndromes (CAPS) represent a genetic form of autoinflammation where mutations in the NLRP3 gene lead to overproduction of the inflammatory molecule IL-1β. Hearing loss is a hallmark feature. The proposed mechanism involves chronic inflammation of the membranes around the brain, which increases the permeability of the barrier between cerebrospinal fluid and the inner ear’s fluid. Inflammatory molecules then seep into the cochlea, triggering damage from within.²² The encouraging news is that drugs blocking IL-1 have shown success in treating CAPS-related hearing loss, supporting the idea that the inflammatory pathway is the direct cause.²³

Why Diagnosis Is So Difficult

There is no single blood test that reliably confirms autoimmune hearing loss. The most studied laboratory marker, a Western blot test for heat shock protein 70 (hsp 70), has a high positive predictive value for steroid responsiveness, around 91%, but its sensitivity is low at about 42%. That means the test is good at confirming the diagnosis when it is positive, but misses more than half of actual cases.²⁴ Other standard inflammatory markers add little beyond what can already be detected by simpler tests like the sedimentation rate.

In practice, clinicians often rely on a combination of the hearing loss pattern and the response to treatment. The typical high-risk profile is a middle-aged patient, often female, with hearing loss affecting both ears unevenly, with or without dizziness, and sometimes with an existing systemic autoimmune disease like rheumatoid arthritis.²⁵ A positive response to corticosteroids is itself considered supportive evidence of an autoimmune cause.²⁶

Audiometric patterns provide additional clues. The most common pattern on a hearing test is a downsloping curve, meaning higher-frequency sounds are lost first, but upsloping, flat, and other configurations have all been documented. The onset can be progressive, sudden, or fluctuating, with progressive onset being the most common at roughly half of cases.²⁷ That variability is exactly what makes autoimmune hearing loss a chameleon, able to look like age-related decline one day and Ménière’s disease the next.

Treatment and What Happens When Drugs Fail

Corticosteroids are the first-line treatment for autoimmune hearing loss. They work by broadly suppressing the immune response, and when a patient’s hearing improves on steroids, it reinforces the autoimmune diagnosis. However, long-term steroid responsiveness is poor; many patients initially improve but lose those gains over time as the disease flares again or steroid side effects force a dosage reduction.²⁸ Intratympanic steroid injections, delivered directly through the eardrum into the middle ear space, offer a local alternative that avoids many systemic side effects and can be used as a supplement or substitute when oral steroids are not tolerated.²⁹

Beyond steroids, a range of biologic drugs targeting specific immune pathways have been tried, including those that block tumor necrosis factor, interleukin-1, and B-cell activity. The results so far have been mixed. Some patients see improvements in vertigo and tinnitus, but a clear, consistent benefit for the hearing loss itself has not been demonstrated. The rarity of AIED makes it nearly impossible to run the large randomized trials needed to settle the question, and the patients who do participate tend to have very different underlying causes lumped under one label.³⁰

Cochlear Implants When Hearing Cannot Be Saved

When medical therapy fails and hearing loss becomes severe or profound, cochlear implantation enters the picture. There has been reasonable concern that an ongoing autoimmune process might attack the implant, promote scarring inside the cochlea, or produce unreliable outcomes. The evidence so far is reassuring. A systematic review found that nearly all patients with autoimmune hearing loss who received cochlear implants showed improved hearing afterward: roughly a third continued improving over time, a third improved and then plateaued, and a third remained stable at their post-surgical level. The complication rate was comparable to that of cochlear implantation in general, though a small number of patients with secondary AIED (hearing loss caused by a systemic autoimmune disease) had poorer initial results.³¹

A meta-analysis quantifying these outcomes found large, statistically significant improvements in both speech recognition and word recognition scores after implantation.³² Some studies tracked patients for five years or more and found that speech perception continued climbing well beyond the first year, with word recognition scores rising from near-zero before surgery to above 90% at the five-year mark.³³ The key takeaway is that an autoimmune cause should not disqualify someone from being considered for a cochlear implant.

Genetic Autoinflammation and Hearing Loss in Families

The discovery of NLRP3 mutations in families with inherited sensorineural hearing loss has opened a new chapter in understanding how the immune system and the ear intersect. These mutations cause the NLRP3 inflammasome, a molecular alarm system in immune cells, to stay permanently activated. The result is a constant drip of inflammatory signaling, particularly interleukin-1β, that damages the cochlea over time.²³ In cryopyrin-associated periodic syndromes, the hearing loss is dominantly inherited, meaning a child has a 50% chance of inheriting the mutation from an affected parent.

What makes these conditions clinically significant beyond genetics is that they respond to targeted therapy. IL-1 blockers like anakinra have stabilized or improved hearing in CAPS patients, which provides both a treatment and a proof of concept: if shutting down a specific inflammatory molecule reverses hearing loss, that molecule was likely causing the damage.²² Identifying these genetic forms matters because the treatment strategy is entirely different from standard autoimmune hearing loss management. A patient with an NLRP3 mutation does not need broad immunosuppression; they need precise IL-1 blockade.